Orakl Oncology
Latest round
- Seed
Last raised
- Dec 2024
Total raised
- $12M
Investors
- 2
About Orakl Oncology
Based in France, Orakl Oncology provides technology solution for the development of oncology personalized treatment. As of 2023, the company is headed by its CEO Fanny Jaulin, who co-founded the firm along with Diane-Laure Pagès and Gustave Ronteix. The company offer a platform that combine technology, biology and artificial intelligence to provide the cancer treatment and drug development. The firm AI based platform leverage tumor avtar which mimic real-life response to drugs and matches tumor model with detailed clinical and omics data.
Who invested in Orakl Oncology
2 investors across 1 round
See all investors in Orakl Oncology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Dec 3, 2024
Amount
$12M
Investors
Questions about Orakl Oncology
Who invested in Orakl Oncology?
Orakl Oncology has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Orakl Oncology raised?
Orakl Oncology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Orakl Oncology last raise money?
Orakl Oncology's most recent round on record is a Seed, in Dec 2024.
What does Orakl Oncology do?
Based in France, Orakl Oncology provides technology solution for the development of oncology personalized treatment.
Where is Orakl Oncology headquartered?
Orakl Oncology is headquartered in France.
Which VCs invest in companies like Orakl Oncology?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Orakl Oncology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Orakl Oncology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.